Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, by Drug Class (Thrombopoietin Receptor Agonists, Thrombopoietic Agents, and Others), by Route of Administration (Oral and Injectable), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 1,327.5 million in 2020 and is expected to exhibit a CAGR of 5.0% during the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.
Global Chemotherapy-induced Thrombocytopenia Therapeutics Market- Impact of Coronavirus (COVID-19) Pandemic
Lockdown in various countries due to the pandemic has placed an economic burden on the private healthcare sector. The COVID-19 pandemic has impacted virtually every aspect of cancer care and research from new risks for cancer patients to disrupting the delivery of cancer treatment and the continuity of cancer research. Patients with cancer are required to visit health care facilities more than patients with other diseases. The treatment of patients with cancer require a full involvement of multidisciplinary teams throughout the disease trajectory from diagnosis to survivorship or end-of-life care. During the disease course, patients require multiple hospital visits for assessment by different clinicians and to undergo laboratory or imaging tests for diagnosis, staging or monitoring of treatment effects in addition to different types of procedures and interventions. Data from different countries show cancer patients are slightly at a higher risk to suffer from COVID-19 than other people. If the cancer patient develops COVID– 19 infection, the chances of organ related complication increases as some might have gone through treatment in terms of radiation therapy, or chemotherapy which automatically suppress the immunity. The negative impact of the pandemic is likely to be greater in low and middle income countries with limited resources, poor infrastructure, shortage of health care providers and organized care teams, scarcity of medical supplies and personal protective equipment (PPE), and poor access to technology resulting in a lack of ability to provide and deliver critical care.
The increasing number of product approvals from regulatory bodies is expected to drive growth of the global chemotherapy-induced thrombocytopenia therapeutics market during the forecast period. For instance, in January 2019, the U.S. FDA granted orphan drug designation to avatrombopag for the treatment of chemotherapy-induced thrombocytopenia. This drug also got approval from US Food and Drug Administration in the U.S. in June, 2019 for the treatment of thrombocytopenia among adults facing chronic liver disease.
The increasing number strategic acquisitions by market players is expected to drive the global chemotherapy-induced thrombocytopenia therapeutics market growth in the near future. For instance, in November 2019, Swedish Orphan Biovitrum AB acquired Dova Pharmaceuticals, Inc., a company focused on developing and commercializing drug candidates for rare diseases. Through this acquisition, Doptelet (avatrombopag) drug was added to the Swedish Orphan Biovitrum AB’s portfolio. Doptelet (avatrombopag) is indicated for treatment of low blood platelet count.
The increasing number of pipeline products for the treatment of chemotherapy-induced thrombocytopenia is expected to drive the market growth. For instance, Nplate (Amgen Inc.) is a thrombopoietin receptor agonist (TPO-RA). It is in phase 3 clinical trial for the treatment of chemotherapy-induced thrombocytopenia (CIT). The phase 3 trial was initiated in February, 2020.
Browse 36 Market Data Tables and 29 Figures spread through 156 Pages and in-depth TOC on Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, by Drug Class (Thrombopoietin Receptor Agonists, Thrombopoietic Agents, and Others), by Route of Administration (Oral and Injectable), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Forecast to 2027"
To know the latest trends and insights related to Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, click the link below:
The increasing number of clinical trials to develop drug for the treatment of chemotherapy-induced thrombocytopenia is expected to drive growth of the global chemotherapy-induced thrombocytopenia therapeutics market. For instance, in September 2019, according to a phase 2 study reported of romiplostim treatment of chemotherapy-induced thrombocytopenia in Journal of Clinical Oncology, the treatment with Romiplastin (injectable drug) was effective in rapidly correcting chemotherapy-induced thrombocytopenia. Therefore such factors are expected to aid in growth of the segment. Moreover, in November 2019, a clinical trial was conducted for Romiplostim Research at Memorial Sloan Kettering Cancer Center and included 23 patients with chemotherapy-induced thrombocytopenia with platelets <100,000/mL for at least four weeks despite delay or dose reduction of chemotherapy.
Key Takeaways of the Global Chemotherapy-induced Thrombocytopenia Therapeutics Market:
Joining thousands of companies around the world committed to making the Excellent Business Solutions.